Profile data is unavailable for this security.
About the company
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
- Revenue in EUR (TTM)0.00
- Net income in EUR-3.35m
- Incorporated--
- Employees44.00
- LocationOryzon Genomics SASant Ferran 74CORNELLA DE LLOBREGAT 08940SpainESP
- Phone+34 935151313
- Fax+34 933774028
- Websitehttp://www.oryzon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eurofins-Cerep SA | 46.17m | 9.21m | 109.96m | 233.00 | 11.94 | 1.83 | 9.82 | 2.38 | 1,826.41 | 1,826.41 | 9,160.00 | 11,939.29 | 0.6814 | 1.66 | 6.04 | 220,892.00 | 13.60 | 15.19 | 16.06 | 18.94 | 85.57 | 67.30 | 19.95 | 19.72 | 5.17 | 112.42 | 0.00005 | 0.00 | 14.45 | 14.30 | 17.09 | 24.52 | -- | -- |
| Medica SpA | 63.83m | 3.26m | 111.49m | 706.00 | 34.17 | 2.26 | 11.48 | 1.75 | 0.7727 | 0.7727 | 15.11 | 11.68 | 0.5817 | 1.07 | 5.22 | 90,672.33 | 2.26 | -- | 3.31 | -- | 58.28 | -- | 3.88 | -- | 0.8276 | 4.21 | 0.3487 | -- | 16.13 | -- | -12.52 | -- | -- | -- |
| Arcticzymes Technologies ASA | 10.07m | 1.59m | 112.02m | 61.00 | 70.24 | 4.29 | 52.68 | 11.12 | 0.3702 | 0.3702 | 2.35 | 6.07 | 0.3618 | 0.5941 | 2.43 | -- | 5.69 | 15.52 | 6.12 | 17.16 | 95.02 | 96.69 | 15.74 | 33.10 | 12.43 | -- | 0.0392 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
| DBV Technologies SA | 4.91m | -94.80m | 114.77m | 88.00 | -- | 0.7443 | -- | 23.36 | -1.01 | -1.01 | 0.0521 | 1.60 | 0.0209 | -- | 0.3738 | 71,189.72 | -40.35 | -64.67 | -46.22 | -80.94 | -- | 91.59 | -1,929.97 | -1,345.10 | -- | -- | 0.0128 | -- | -15.14 | -18.45 | 2.08 | -- | -38.41 | -- |
| Adocia SA | 5.73m | -20.55m | 120.53m | 100.00 | -- | -- | -- | 21.05 | -2.36 | -2.36 | 0.6532 | -1.90 | 0.1823 | -- | 16.79 | 55,048.08 | -65.43 | -25.65 | -341.43 | -37.22 | -- | -- | -358.85 | -101.11 | 0.5924 | -2.78 | 2.81 | -- | 692.73 | -10.08 | 69.67 | -- | -40.08 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 121.03m | 62.00 | -- | 5.22 | -- | 54.35 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Transgene SA | 7.63m | -22.33m | 122.03m | 158.00 | -- | 7.79 | -- | 15.99 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Santhera Pharmaceuticals Holding AG | 5.28m | -66.16m | 122.67m | 46.00 | -- | -- | -- | 23.23 | -27.26 | -27.26 | 1.35 | -4.65 | 0.0723 | 34.23 | 3.54 | 112,217.40 | -90.56 | -54.38 | -250.35 | -75.34 | 29.39 | 78.16 | -1,253.16 | -209.10 | 0.0778 | -2.29 | -- | -- | 568.53 | -20.10 | -27.87 | -- | 23.14 | -- |
| Hansa Biopharma AB | 14.20m | -72.33m | 123.19m | 166.00 | -- | -- | -- | 8.67 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Futura Medical PLC | 3.62m | -7.61m | 124.82m | 12.00 | -- | 19.51 | -- | 34.46 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 4.73 | -- | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | -- | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Oryzon Genomics SA | 0.00 | -3.35m | 124.82m | 44.00 | -- | 1.49 | -- | -- | -0.0533 | -0.0533 | 0.00 | 1.34 | 0.00 | 143.81 | -- | 0.00 | -3.18 | -4.20 | -3.82 | -4.82 | -- | -- | -- | -- | 0.8694 | -2.93 | 0.1434 | -- | -- | -- | 20.76 | -- | 15.52 | -- |
| Molecular Partners AG | 7.20m | -63.39m | 124.98m | 168.00 | -- | 0.6257 | -- | 17.36 | -1.89 | -1.89 | 0.2147 | 5.37 | 0.0306 | -- | 4.74 | 41,892.86 | -26.91 | -11.83 | -28.90 | -14.69 | -- | 99.28 | -880.70 | -45.30 | -- | -70.97 | 0.0203 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Photocure ASA | 42.40m | 22.61k | 127.25m | 106.00 | 7,715.88 | 3.11 | 53.74 | 3.00 | 0.0072 | 0.0072 | 18.58 | 17.79 | 0.7001 | 0.8203 | 9.37 | -- | 0.0375 | -3.09 | 0.0429 | -3.56 | 94.78 | 93.64 | 0.0535 | -5.19 | 4.32 | -- | 0.00 | -- | 27.35 | 22.50 | 100.37 | -- | 49.83 | -- |
| Heidelberg Pharma AG | 9.05m | -18.28m | 138.42m | 98.00 | -- | 3.07 | -- | 15.29 | -0.3957 | -0.3957 | 0.196 | 0.968 | 0.1222 | 0.2187 | 11.87 | 95,273.69 | -24.68 | -43.91 | -33.18 | -64.34 | 79.75 | 52.13 | -201.94 | -206.24 | 2.22 | -- | 0.104 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
| Newron Pharmaceuticals SpA | 9.05m | -16.22m | 138.56m | 23.00 | -- | -- | -- | 15.31 | -0.8886 | -0.8886 | 0.496 | -1.64 | 0.2873 | -- | 4.57 | 384,865.20 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
Data as of Apr 26 2024. Currency figures normalised to Oryzon Genomics SA's reporting currency: Euro EUR
0.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 136.22k | 0.22% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 90.29k | 0.15% |
| Santander Private Banking Gestion SA SGIICas of 31 Dec 2023 | 50.00k | 0.08% |
| Gescooperativo SA SGIICas of 31 Dec 2023 | 47.91k | 0.08% |
| Tressis Gesti�n SGIIC SAas of 31 Dec 2023 | 45.00k | 0.07% |
| Solventis SGIIC SAas of 31 Dec 2023 | 20.00k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 04 Apr 2024 | 12.54k | 0.02% |
| Gesiuris Asset Management SGIIC SAas of 31 Dec 2023 | 8.00k | 0.01% |
| Gesti�n de Patrimonios Mobiliarios AV SAas of 31 Dec 2023 | 4.00k | 0.01% |
| Andbank Wealth Management SGIIC SAUas of 31 Dec 2023 | 200.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
